Detection Of CA125 Research Articles

Does serum CA125 have clinical value for follow-up monitoring of postoperative patients with epithelial ovarian cancer? Results of a 12-year study

BackgroundThe detection of CA125 has been used in the follow up of ovarian cancer. At present, some scholars believe that serum CA125 has no clinical value for the follow-up monitoring the recurrence for postoperative patients with epithelial ovarian cancer, but in our clinical follow-up found that when the serum CA125 value is <35 U/ml, postoperative patients of epithelial ovarian carcinoma had already showed recurrent lesions in some ecological and imaging examinations or in laparotomy exploration and biopsy, and we given the patients timely treatment, the prognosis were improved.MethodsRetrospective analysis the values of serum CA125 of 342 postoperative patients of epithelial ovarian carcinoma, consisting of 296 non-recurrent and 46 recurrent cases, as well as 3175 cases of menopausal women and 603 cases of postoperative patients of gynecological malignant tumor for the follow-up from January 2005 to December 2016.ResultsThe median value of CA125 for non-recurrent patients of epithelial ovarian carcinoma is 8.9 U/ml, the median value of CA125 for non-recurrent patients of epithelial ovarian carcinoma is 29.7 U/ml; for menopausal women, 8.1 U/ml; and for postoperative patients of gynecological malignant tumor, 7.2 U/ml, whereas the mean ± standard deviation is 9.0 ± 1.9 U/ml, 31.3 ± 16.2U/ml, 8.0 ± 1.1 U/ml, and 6.8 ± 2.1 U/ml, respectively.ConclusionsIf the value of the CA125 for postoperative patients of epithelial ovarian carcinoma between 10 and 35 U/ml indicates a relative risk of recurrence. When the value of CA125 is higher than 10 U/ml and continuously increased, need to be vigilant and should be combined with imaging examination (PET-CT). This result may improve the prognosis for recurrent patients because of the early detection of recurrent lesions and early retreatment.

Integrated Microfluidic Lectin Barcode Platform for High-Performance Focused Glycomic Profiling.

Protein glycosylation is one of the key processes that play essential roles in biological functions and dysfunctions. However, progress in glycomics has considerably lagged behind genomics and proteomics, due in part to the enormous challenges in analysis of glycans. Here we present a new integrated and automated microfluidic lectin barcode platform to substantially improve the performance of lectin array for focused glycomic profiling. The chip design and flow control were optimized to promote the lectin-glycan binding kinetics and speed of lectin microarray. Moreover, we established an on-chip lectin assay which employs a very simple blocking method to effectively suppress the undesired background due to lectin binding of antibodies. Using this technology, we demonstrated focused differential profiling of tissue-specific glycosylation changes of a biomarker, CA125 protein purified from ovarian cancer cell line and different tissues from ovarian cancer patients in a fast, reproducible, and high-throughput fashion. Highly sensitive CA125 detection was also demonstrated with a detection limit much lower than the clinical cutoff value for cancer diagnosis. This microfluidic platform holds the potential to integrate with sample preparation functions to construct a fully integrated “sample-to-answer” microsystem for focused differential glycomic analysis. Thus, our technology should present a powerful tool in support of rapid advance in glycobiology and glyco-biomarker development.

The diagnosis and pathological value of combined detection of HE4 and CA125 for patients with ovarian cancer.

ObjectiveTo evaluate the value of individual and combined measurement of human epididymis protein 4 (HE4) and cancer antigen 125 (CA-125) in the diagnosis of ovarian cancer.MethodsA clinical case-control study was performed in which the levels of serum HE4 and CA-125 of subjects with malignant, borderline, benign ovarian tumors and healthy women were measured before surgery. An immunohistochemistry method was used to measure the expression of HE4 in different tissues. Statistical analysis was performed to determine the relationship between the level of HE4 and the pathologic type as well as the stage of the ovarian tumors.ResultsThe level of HE4 in the serum was significantly elevated in the malignant ovarian cancer group compared with other groups. Women with benign ovarian tumors and non-neoplastic lesions, and healthy women were designated as references. When the level of HE4 in the serum was 58.66 pmol/L, the sensitivity and specificity of HE4 in diagnosing malignant ovarian tumors was 82.35% and 96.03%, respectively. The level of HE4 was negatively correlated with the differentiation extent of the tumors whereas positively correlated to the clinical staging. In the groups of malignant and borderline tumors, the levels of HE4 were higher than the other groups. The expression of HE4 was significant higher in the serous types of ovarian tumors than that of the mucous types (P<0.05). The level of HE4 in the serum and tissues were positively correlated with each other.ConclusionHE4 can be used as a novel clinical biomarker for predicting malignant ovarian tumors and its expression was closely related with the clinical pathological features of malignant ovarian tumors.

Emerging role of tumor markers and biochemistry in the preoperative invasive assessment of intraductal papillary mucinous neoplasm of the pancreas

BackgroundWe explored the significance of laboratory examinations in predicting invasive carcinoma derived from intraductal papillary mucinous neoplasm (IPMN). MethodsWe retrospectively reviewed preoperative laboratory examination data and postoperative pathological data for 87 patients with IPMN who underwent surgical resection at Peking Union Medical College Hospital from February 2008 to March 2015. ResultsHistological review of 87 patients with surgical resection revealed 4 cases of mild-grade dysplasia (4.6%), 34 cases of intermediate dysplasia (39.1%), 16 cases of high-grade dysplasia (18.4%) and 33 cases of invasive carcinoma (37.9%). The first 3 grades were considered noninvasive. In univariate analyses, increased serum concentrations of CA19-9 (p<0.001), CA24-2 (p<0.001), CEA (p<0.001) and hsCRP (p=0.027) were significantly associated with invasive carcinoma. Multivariate analysis showed that increased serum concentrations of CA19-9 (p=0.009) and CEA (p=0.042) were significant independent predictors of invasiveness. The combination of CA19-9, CA 24-2 and CEA improved the accuracy of prediction, and the sensitivity and specificity were 71.0% and 87.7% respectively. ConclusionsThe development of diagnostic laboratory tests has important implications for pre-operative IPMN evaluation. Increased serum CA19-9 and CEA concentrations are independent predictors of invasive carcinoma derived from IPMN, and increased serum CA24-2 and hsCRP concentrations are significantly associated with the risk of invasiveness. Combined detection of CA19-9+CA24-2+CEA proved to be the most accurate in predicting the invasiveness of IPMN.

Applicative Value of Serum CA19-9, CEA, CA125 and CA242 in Diagnosis and Prognosis for Patients with Pancreatic Cancer Treated by Concurrent Chemoradiotherapy.

To evaluate the application value of serum CA19-9, CEA, CA125 and CA242 in diagnosis and prognosis of pancreatic cancer cases treated with concurrent chemotherapy. 52 patients with pancreatic cancer, 40 with benign pancreatic diseases and 40 healthy people were selected. The electrochemiluminescence immunoassay method was used for detecting levels of CA19-9, CEA and CA125, and a CanAg CA242 enzyme linked immunoassay kit for assessing the level of CA242. The Kaplan-Meier method was used for analyzing the prognostic factors of patients with pancreatic cancer. The Cox proportional hazard model was applied for analyzing the hazard ratio (HR) and 95% confidential interval (CI) for survival time of patients with pancreatic cancer. The levels of serum CA19-9, CEA, CA125 and CA242 in patients with pancreatic cancer were significantly higher than those in patients with benign pancreatic diseases and healthy people (P<0.001). The sensitivity of CA19-9 was the highest among these, followed by CA242, CA125 and CEA. The specificity of CA242 is the highest, followed by CA125, CEA and CA19-9. The sensitivity and specificity of joint detection of serum CA19-9, CEA, CA125and CA242 were 90.4% and 93.8%, obviously higher than single detection of those markers in diagnosis of pancreatic cancer. The median survival time of 52 patients with pancreatic cancer was 10 months (95% CI7.389~12.611).. Patients with the increasing level of serum CA19-9, CEA, CA125, CA242 had shorter survival times (P=0.047. 0.043, 0.0041, 0.029). COX regression analysis showed that CA19-9 was an independent prognostic factor for patients with pancreatic cancer (P=0.001, 95%CI 2.591~38.243). The detection of serum tumor markers (CA19.9, CEA, CA125 and CA242) is conducive to the early diagnosis of pancreatic cancer and joint detection of tumor markers helps improve the diagnostic efficiency. Moreover, CA19-9 is an independent prognostic factor for patients with pancreatic cancer.

Ultrasensitive photoelectrochemical immunoassay for CA19-9 detection based on CdSe@ZnS quantum dots sensitized TiO2NWs/Au hybrid structure amplified by quenching effect of Ab2@V(2+) conjugates.

A novel, enhanced photoelectrochemical immunoassay was established for sensitive and specific detection of carbohydrate antigen 19-9 (CA19-9, Ag). In this protocol, TiO2 nanowires (TiO2NWs) were first decorated with Au nanoparticles to form TiO2NWs/Au hybrid structure, and then coated with CdSe@ZnS quantum dots (QDs) via the layer-by-layer method, producing TiO2NWs/Au/CdSe@ZnS sensitized structure, which was employed as the photoelectrochemical matrix to immobilize capture CA19-9 antibodies (Ab1); whereas, bipyridinium (V(2+)) molecules were labeled on signal CA19-9 antibodies (Ab2) to form Ab2@V(2+) conjugates, which were used as signal amplification elements. The TiO2NWs/Au/CdSe@ZnS sensitized structure could adequately absorb light energy and dramatically depress electron-hole recombination, resulting in evidently enhanced photocurrent intensity of the immunosensing electrode. While target Ag were detected, the Ab2@V(2+) conjugates could significantly decrease the photocurrent detection signal because of strong electron-withdrawing property of V(2+) coupled with evident steric hindrance of Ab2. Thanks to synergy effect of TiO2NWs/Au/CdSe@ZnS sensitized structure and quenching effect of Ab2@V(2+) conjugates, the well-established photoelectrochemical immunoassay exhibited a low detection limit of 0.0039 U/mL with a wide linear range from 0.01 U/mL to 200 U/mL for target Ag detection. This proposed photoelectrochemical protocol also showed good reproducibility, specificity and stability, and might be applied to detect other important biomarkers.

Predictive value of preoperative detection of CEA and CA199 for prognosis in patients with stage II-III colorectal cancer

To investigate the predictive value of preoperative detection of CEA and CA199 for prognosis in patients with stage II-III colorectal cancer (CRC). Clinicopathological and follow-up data of 266 patients with stage II-III colorectal cancer confirmed by pathology and undergoing radical resection in our department from 2004 to 2006 were retrospectively analyzed. The 5-year overall survival (OS) and disease-free survival (DFS) between normal CEA patients and increased CEA ones, and normal CA199 patients and increased CA199 ones were compared respectively. Moreover, the risk factors of OS and DFS were examined. Among these 266 patients, 119 (44.7%) had preoperative elevated CEA, and 74 (27.8%) had increased CA199. The median follow-up time was 63 months. Kaplan-Meier survival curves indicated that patients with elevated preoperative CEA had worse 5-year OS (54.6% vs. 72.8%, P=0.001) and DFS (75.2% vs. 83.3%, P=0.042) than those with normal CEA respectively. Meanwhile, patients with elevated CA199 had worse OS (45.9% vs. 71.9%, P=0.000) and DFS (74.2% vs. 81.8%, P=0.047) than those with normal CA199 respectively. Multivariate analysis revealed that male (HR=3.016, 95% CI: 1.536-5.919, P=0.001), lymph node metastasis (HR=2.278, 95% CI: 1.272-4.081, P=0.006), and preoperative elevated CEA (HR=1.794, 95%CI: 1.022-3.149, P=0.042) were independent prognostic factors of DFS. While vascular thrombosis (HR=2.041, 95% CI: 1.294-3.221, P=0.002), lymph node metastasis (HR=2.480, 95% CI:1.548-3.972, P=0.000), and preoperative elevated CA199 (HR=2.145, 95% CI:1.414-3.254, P=0.000) were independent prognostic factors of OS in patients with stage II-III CRC. Combined detection of preoperative CEA and CA199 can be used in evaluating the prognosis of patients with stage II-III CRC.

Abstract 369: Association between tumor infiltrating immune cells, circulating tumor cells in blood and disseminated tumor cells in the bone marrow in patients with primary ovarian cancer

Abstract Background: We recently showed that the presence of disseminated tumor cells (DTCs) in the bone marrow (BM) and circulating tumor cells (CTCs) in blood of primary ovarian cancer patients significantly correlated with reduced progression free survival (PFS) and overall survival (OS). On the one hand, this negative prognostic impact might be related to different factors like chemotherapy resistant and stem cell like cells. On the other hand, the microenvironment of the primary tumor might influence tumor cell spread and thus, outcome of the disease. Here we analyzed whether infiltrating leukocytes in the tumor (TILs) and/or stroma (SILs) are associated with DTCs before and after therapy as well as with CTCs before therapy in patients with primary ovarian cancer. Patients and Methods: DTCs before (n = 145) and after therapy (n = 57) were studied using immunocytochemistry applying the pan cytokeratin (CK) antibody A45-B/B3. 2 × 5 ml bloods of 111 patients were analyzed for CTCs with the AdnaTest OvarianCancer (AdnaGen AG, Langenhagen, Germany) for the detection of EpCAM, MUC-1, CA-125 and beta-Actin transcripts. Tissue microarrays of all patients were stamped from paraffin embedded specimens and 5μm thick sections were prepared and subjected to immunohistochemical analysis using antibodies against human CD4 (Zytomed Systems, Clone IF6, 1:40), CD8 (DakoCytomation, Clone C8/144B, 1:150) and CD68 (DakoCytomation,Clone PG-M1, 1:500), respectively. Each tissue microarray has been evaluated for TILs and SILs by counting manually, using a 10x and 20x objective lens. Statistical analysis was conducted with the R programming language (version 3.02) and ANOVA, Chi-squared test, and when indicated, Fisher's exact test has been used to check for independence. Results: Before therapy, DTCs were detected in 51/145 patients (35%) and after therapy in 24/57 patients (42%). CTCs were detected in 24/111 patients (22%) before therapy. In general, the highest infiltration of lymphocytes was found in the stroma. Whereas high numbers of CD8 were detected in the stroma and the tumor, high numbers of CD4 and CD68 infiltrates were mainly found in the stroma. The expression of CD4 (SIL) and CD8 (SIL) was significantly associated with the presence of CTCs (p = 0.04) whereas CD4 (SIL) significantly correlated with DTCs before (p = 0.03) and CD8 (SIL) with DTCs after therapy (p = 0.04). No association was found between DTCs/CTCs and the expression of CD68. Conclusion: Here we demonstrate significant associations between infiltrating lymphocytes and the presence of DTCs and CTCs. Ongoing studies are now including the expression of CD20 and CD45 and final statistical analysis, including immune signatures, all clinical parameters, PFS and OS, will give deeper insights in the interaction of tumor infiltrating immune cells and tumor cell dissemination. Citation Format: Issam Chebouti, Agnes Bankfalvi, Christoph Friedrich, Rainer Kimmig, Sabine Kasimir-Bauer. Association between tumor infiltrating immune cells, circulating tumor cells in blood and disseminated tumor cells in the bone marrow in patients with primary ovarian cancer. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 369. doi:10.1158/1538-7445.AM2015-369

Ultrasensitive immunoassay for CA125 detection using acid site compound as signal and enhancer

A novel sensitive electrochemical immunosensor was proposed for detection of CA125 based on ferrocenecarboxylic acid (FA), HCl-doped polyaniline (H-PANI) and chitosan hydrochloride (CS-HCl), which were used as substrate materials to generate signal and to enlarge specific surface area. The composite of these three materials (acid center compound, FA@H-PANI@CS-HCl) can be connected by hydrogen (H) in each molecule. Ag@Co3O4 nanosheets were used in the immunosensor to amplify the antibody capacity and to enhance the sensitivity of the immunoassay. This kind of sensor was novel, concise and it is the first time to be used in the detection of CA125. The biosensor exhibited low detection limit (0.25pg/mL) and wide linear range (0.001–25ng/mL). The stability, selectivity and reproducibility were acceptable. Serum sample analysis proved that the proposed sensor owned well precision and it might be used in potential clinic testing application in the future.

Application of Joint Detection of AFP, CA19-9, CA125 and CEA in Identification and Diagnosis of Cholangiocarcinoma.

To explore the application of joint detection of serum AFP, CA19-9, CA125 and CEA in identification and diagnosis of cholangiocarcinoma (CC). The levels of serum AFP, CA19-9, CA125 and CEA of both 30 patients with CC and 30 patients with hepatocellular carcinoma (HCC) were assessed. Receiver operating characteristic (ROC) curves were used to evaluate the diagnostic effects of single and joint detection of those 4 kinds of tumor markers for CC. The levels of serum CA19-9, CA125 and CEA in CC patients were higher than that in HCC patients,whereas that of serum AFP was significantly lower s. The area under ROC curve of single detection of serum AFP, CA19-9, CA125 and CEA were 0.05, 0.86, 0.84 and 0.83, with the optimal cutoff values of 15.4 ng/ml, 125.1 U/ml, 95.7 U/ml and 25.9 ng/ml, correspondingly, and the percentage correct single diagnosis was <79%. With joint detection, the diagnostic effect of combined AFP, CA19-9, CA125 and CEA was the highest, with an area under the ROC curve of 0.94 (95%CI 0.88~0.99). Single detection of serum CA19-9, CA125 and EA is not meaningful. The sensitivity, specificity, the rate of correct diagnosis and the area under ROC curve of joint detection of AFP, CA19-9, CA125 and CEA are highest, indicating that the joint detection of these 4 tumor markers is of great importance in the diagnosis of CC.

Tag-femtosecond laser-induced breakdown spectroscopy for the sensitive detection of cancer antigen 125 in blood plasma.

Successful treatment of cancers requires detecting early signs of the disease. One promising way to approach this is to develop minimally invasive tests for the sensitive and specific detection of biomarkers in blood. Irrespective of the detection approach one uses, this remains a challenging task because biomarkers are typically present in low concentrations and there are signals that interfere strongly with prevailing compounds of human fluids. In this paper, we show that elemental encoded particle assay coupled with femtosecond laser-induced breakdown spectroscopy for simultaneous multi-elemental analysis can significantly improve biomarker detectability. An estimated near single molecule per particle efficiency of this method leads to sensitive detection of ovarian cancer biomarker CA125 in human blood plasma. This work opens new ways for earlier detection of cancers and for multiplex assay developments in various analytical applications from proteomics, genomics, and neurology fields.

Tumor markers for diagnosis, monitoring of recurrence and prognosis in patients with upper gastrointestinal tract cancer.

To evaluate the value of combined detection of serum CEA, CA19-9, CA24-2, AFP, CA72-4, SCC, TPA and TPS for the clinical diagnosis of upper gastrointestinal tract (GIT) cancer and to analyze the efficacy of these tumor markers (TMs) in evaluating curative effects and prognosis. A total of 573 patients with upper GIT cancer between January 2004 and December 2007 were enrolled in this study. Serum levels of CEA, CA19-9, CA24-2, AFP, CA72-4, SCC, TPA and TPS were examined preoperatively and every 3 months postoperatively by ELISA. The sensitivity of CEA, CA19-9, CA24-2, AFP, CA72-4, SCC, TPA and TPS were 26.8%, 36.2%, 42.9%, 2.84%, 25.4%, 34.6%, 34.2% and 30.9%, respectively. The combined detection of CEA+CA199+CA242+CA724 had higher sensitivity and specificity in gastric cancer (GC) and cardiac cancer, while CEA+CA199+CA242+SCC was the best combination of diagnosis for esophageal cancer (EC). Elevation of preoperative CEA, CA19-9 and CA24-2, SCC and CA72-4 was significantly associated with pathological types (p<0.05) and TNM staging (p<0.05). Correlation analysis showed that CA24-2 was significantly correlated with CA19-9 (r=0.810, p<0.001). The levels of CEA, CA19-9, CA24-2, CA72-4 and SCC decreased obviously 3 months after operations. When metastasis and recurrence occurred, the levels of TMs significantly increased. On multivariate analysis, high preoperative CA72-4, CA24-2 and SCC served as prognostic factors for cardiac carcinoma, GC and EC, respectively. combined detection of CEA+CA199+CA242+SCC proved to be the most economic and practical strategy in diagnosis of EC; CEA+CA199+CA242+CA724 proved to be a better evaluation indicator for cardiac cancer and GC. CEA and CA19-9, CA24-2, CA72-4 and SCC, examined postoperatively during follow-up, were useful to find early tumor recurrence and metastasis, and evaluate prognosis. AFP, TPA and TPS have no significant value in diagnosis of patients with upper GIT cancer.

A label-free electrochemical immunosensor based on poly(thionine)–SDS nanocomposites for CA19-9 detection

In this paper, poly(thionine) doped sodium dodecyl sulphate nanocomposites (PThi–SDS NCs) were synthesised for the first time.

Multiple tumor marker protein chip detection system in diagnosis of pancreatic cancer.

BackgroundThe clinical stage of the disease at diagnosis often determines the prognosis and survival rate of a patient with pancreatic cancer. Early symptoms of pancreatic cancer are often not obvious on imaging (ultrasound, computed tomography (CT), and so on), and when patients present with weight loss, jaundice and abdominal pain and other symptoms, they are usually already in the advanced stages of pancreatic cancer. However, the examination of combined tumor markers might improve their sensitivity or specificity in aiding diagnosis.MethodsTwelve tumor markers including AFP, CEA, NSE, CA125, CA15-3, CA242, CA19-9, PSA, f-PSA, FER, β-HCG and HGH were measured by the protein biochip detection in serum in 235 pancreatic cancer patients, 230 benign pancreatic disease patients and 240 healthy people.ResultsPositive detection rates of tumor markers were: CA19-9 (49.3%), CA125 (45.1%), FER (44.2%), CA242 (42.5%), CEA (38.6%), CA15-3 (36.7%), β-HCG (29.6%), AFP (24.5%), NSE (18.2%), PSA (19.5%), f-PSA (9.4%) and HGH (8.7%) respectively. There was significant difference in CA19-9, NSE, CEA, CA242 and CA125 by multi-tumor marker protein biochip detection among patients with cancer, benign disease and healthy people (P <0.05). The positive rate of 5 tumor markers was 94.9%, and this was much higher than that of any single marker.ConclusionThe detection of CA19-9, NSE, CEA, CA242 and CA125 in the multi-tumor marker protein biochip system is helpful in the diagnosis of pancreatic cancer.

Invited Presentation: SWCNT-Based Fluorescent Immunoprobes for Short-Wave Infrared Cancer Detection

One of the most unusual properties of semiconducting single-walled carbon nanotubes (SWCNT) is the emission of distinct fluorescence peaks at short-wave infrared (SWIR) wavelengths that depend on specific nanotube structure, or (n,m) indices. This emission is promising for biological marker applications because the peaks are spectrally sharp and distinguishable, they fall in a spectral region of very low autofluorescence backgrounds, and the nanotubes are highly resistant to photobleaching. In order to exploit these properties, we are conjugating structure-sorted SWCNTs to antibodies to make novel fluorescent immunoprobes. Our initial approach has involved covalent linkage of generic IgG antibodies to the polyethylene glycol sidearm of a phospholipid surfactant used to noncovalently coat surfaces of individual SWCNTs. We have optimized our protocols by SWIR fluorescence imaging of flow cytometry beads linked to Protein G to capture the SWCNT-antibody conjugates. Studies to generate similar probes against important cancer biomarkers, such as the CA125 (MUC16), a 1.5mD heavily glycosylated mucin that is displayed on the surface of ovarian cancer cells, are in progress. We will describe results of experiments linking the OC125 antibody, which detects an epitope on the CA125 molecule, to (n,m)-sorted SWCNT samples followed by detection of CA125 on cultured ovarian cancer cells.

The value of combined detection of biomarkers in the early diagnosis and treatment of breast cancer

Objective To explore the value of combined detection of CA153,TSGF,CA125 and CEA both in nipple discharge and serum in the early diagnosis and treatment of breast cancer.Methods The serum and nipple discharge from 43cases of breast cancer and 136 cases of benign tumour was collected and tumor markers of CA153,TSGF,CA125 and CEA were detected.Results The nipple discharge and serum levels of CA153,TSGF,CA125 and CEA in bresat cancer patients were significantly higher than those in benign disease and normal women(P＜0.01).The levels of the four tumor markes had a positive correlation with Ki-67,gread,lymph node metastas and tumor recurrence (P＜0.05),and negative correlation with the level of ER and PR (P＜0.05).The sensitivity of the four markes in combination was 97.67％ and specificity was99.03％.Conclusion The dynamic combined detection of CA153,TSGF,CA125 and CEA both in nipple discharge and serum are benefit to early diagnosis and interference and better prewarning markers for monitoring their recurrence and metastasis of breast cancer. Key words: Breast cancer; Nipple discharge; Tumor marker; Diagnosis, differential diagnosis

Combined detection of serum OPN, MIC-1 and CA19-9 for diagnosis of pancreatic cancere

Combined detection of serum OPN, MIC-1 and CA19-9 for diagnosis of pancreatic cancere

Clinical value of serum tumor markers CA19-9, CA125 and CA72-4 in the diagnosis of pancreatic carcinoma

CA125 and CA72-4 are members of a family of high-molecular weight glycosylated proteins and are commonly considered as biomarkers in the diagnosis of ovarian and gastric cancer, respectively. However, recent studies have revealed that these two markers may be of clinical value in the diagnosis of pancreatic cancer. As the availability of data regarding CA72-4 and CA125 in the diagnosis of pancreatic cancer is limited, the aim of this study was to investigate the clinical value of serum tumor markers CA19-9, CA125 and CA72-4 in the diagnosis of pancreatic carcinoma according to logistic regression analysis and receiver operating characteristic (ROC) curves and to investigate the correlation of these markers with tumor TNM stage and location. An immunoradiometric assay was used to measure pre-operative serum CA19-9, CA125 and CA72-4 levels in 75 patients with pancreatic carcinoma and 70 patients with benign pancreatic diseases. The concentrations of serum CA19-9, CA125 and CA72-4 in patients with pancreatic carcinoma were found to be significantly higher (P<0.05) compared with those with benign pancreatic diseases. The combined detection of two serum markers (CA19-9 + CA72-4) yielded a ROC value of 0.895 that was significantly higher compared to others (P<0.05) in distinguishing pancreatic cancer from benign pancreatic diseases. At optimal cut-off, the sensitivity and specificity of combined detection (CA19-9 + CA72-4) were 70.6 and 92.8%, respectively. The concentrations of CA125 and CA19-9 in patients with pancreatic adenocarcinoma were found to be significantly higher (P<0.05) compared with those of pancreatic neuroendocrine carcinoma. In conclusion, the combined detection of CA19-9 and CA72-4) may significantly improve the diagnostic specificity and the serum concentrations of CA125 and CA19-9 are correlated with tumor histological type.

The clinical value of CA125 detection in ovarian endometriosis cyst

Objective To explore the application value of CA125 detection in the diagnosis and treatment of ovarian endometriosis cyst,to provide a reference for clinical diagnosis and treatment.Methods 51 patients with ovarian endometriosis cyst were selected as the observation group,and 51 patients with non endometriosis of benign ovarian cyst were selected as control group.The serum CA125 level was detected and compared between the two growps.Results Before operation,the serum CA125 level of the observation group was (95.29 ± 55.47) U/ml,which was significantly higher than that of the control group (17.96 ± 6.82) U/ml (P ＜ 0.05).In the observation group,serum CA125 level of patients with endometriosis clinical pathological stage Ⅱ-Ⅳ was significantly higher than that of patients with stage Ⅰ (P ＜ 0.05).The endometriosis clinical TNM stage was positively correlated with preoperative serum CA125 level in the observation group (r =0.8795,P ＜ 0.05).The preoperative serum CA125 level in patients with dysmenorrhea score 1 point,2 points,3 points was significantly higher than that in patients with dysmenorrhea score 0 point (P ＜ 0.05).The preoperative serum level of CA125 was positively correlated with dysmenorrhea score in the observation group (r =0.5594,P ＜ 0.05).Conclusion The detection of serum carbohydrate antigen CA125 level has important value in diagnosis,treatment and prognosis of ovarian endometriosis. Key words: Endometriosis ; CA-125 antigen

Cation-exchange antibody labeling for simultaneous electrochemical detection of tumor markers CA15-3 and CA19-9

We report on a new kind of non-covalent multi-label electrochemical immunoassay that was applied to simultaneously quantify the tumor markers CA15-3 and CA19-9. The method employs a nanohybrid composed of an ionomer and conductive titanium dioxide nanoparticles that act as a matrix support for the antibodies. The two antibodies (anti-CA153 and anti-CA199) were labeled (a) with a cobaltous dipyridine complex, and (b) with methylene blue. Labeling is based on cation-exchange interaction rather than on covalent conjugation. The redox potentials of the two labels are separated by an interval of 0.3 V. The resulting sandwich-type immunosensor was read out by differential pulse voltammetry. The potential sites and currents of the two redox probes reflect the concentration of the two analytes. The two analytes were determined with a detection limit of 1.6 U mL−1 for CA19-9, and of 0.3 U mL−1 for CA15-3.